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INTRODUCTION
A study by the World Health Organization has found
that diseases of the central nervous system are af-
fecting a significant portion of the population and
are amongst the leading causes of death in West-
ern societies(2). Although great advances have been
made in our understanding of the pathophysiology
of psychiatric and neurological diseases, signifi-
cant gaps remain in our knowledge about their
ultimate causes. A major problem in the area of af-
fective diseases is the fact that current diagnosis is
mainly based on categorizing the signs and symp-
toms of the syndrome, which limits the ability to
reliably identify biological causes and develop spe-
cific treatments. Unlike other disorders like diabe-
tes and heart disease where biological markers
are at hand that allow the physician to come up
with a more reliable diagnosis there are currently
no such markers available for affective diseases.
Here the only means for diagnosis is the Diagnos-
tic and Statistical Manual of Mental Disorders (DSM)
(3). This manual systematically identifies different
mental illnesses according to a list of symptoms
but does in no way address the underlying cause
of the disease. A major goal in the area of affective
disorders is therefore the identification of markers
that can categorize subsets of subjects in a consis-
tent manner. This will allow a more precise defini-
tion and categorization of affective disorders and
in turn facilitate investigations of the pathogenesis
of the diseases and enhance our ability for treat-
ment.
Proteomic technologies promise to be of great value
in molecular medicine, particularly in the detec-
tion and discovery of disease markers. Whereas
there are multiple lesions on the genome that dif-
fer for each individual there are common protein
signatures for polygenic diseases like affective and
neurological disorders. The proteome is therefore
thought to be more directly related to the pheno-
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type of an organism and hence protein profiling will
result in the most precise understanding of dis-
ease mechanisms as well as the molecular effects of
drugs.
Protein amounts and differential modifications
are potential biomarkers in tissues and body flu-
ids. The ultimate goal of proteomics in medicine is
therefore to provide quantitative and qualitative data
of sample proteins that reflect a certain phenotype,
disease state or a response to disease treatment.
In the course of our studies we have found that
animal models for disease show a high success rate
for the identification of biomarkers due to the rather
homogeneous genetic background that the animals
have. Differences in protein expression between
diseased and control animals are therefore more
likely to be related to the disease process. The ques-
tion remains how relevant the identified markers
in the mouse model are for the disease in humans.
Whereas this is less of an issue when specimens
from patients are used as the source for biomarker
discovery the great “background noise” due to in-
dividual variability combined with the limited sam-
ple amount makes the analysis of human samples
orders of magnitude more challenging than those
carried out with animal models.
BIOMARKER DISCOVERY PLATFORMS
1. Mouse Model For Trait Anxiety
The manifestation of anxiety in a number of psyc-
hiatric disorders such as anxiety disorder, depres-
sion, panic attacks, phobias, obsessive-compulsive
disorders and post-traumatic stress disorders (4) high-
lights the importance of gaining a better understan-
ding of associated reliable biomarkers in animal mod-
els. A relevant animal model to study behavioral,
neuroendocrine and genetic concomitants of trait
anxiety including psychopathology should represent
a good approximation to score symptoms of anxiety
disorders and also comorbid depression (4). Genetic
approaches currently available in the mouse make
this model organism particularly powerful for the
functional analysis of candidate genes and in defin-
ing gene products underlying trait anxiety and
depression (5).In order to avoid inter-strain com-
parisons, likely to reveal differences in more than
just anxiety-related indices, my colleague Rainer
Landgraf, who is heading the Behavioral Neuroen-
docrinology research group at the Max Planck In-
stitute of Psychiatry, has used intra-strain breeding
approaches to focus on particular traits, including
anxiety-(6) and depression-like behavior (7) .The
technique of selective bidirectional breeding en-
hances the representation of genetic material asso-
ciated with a particular trait shifting the animals’
phenotype bidirectionally from the strain mean.
Following this approach the Landgraf group has
managed to generate and validate CD1 mouse lines
of hyper-anxious (HAB-M) and hypo-anxious (LAB-M)
phenotypes as model of extremes in trait anxiety (8).
Using classical proteomics approaches we have
been able to identify two biomarkers that reliably
distinguish the HAB-M and LAB-M phenotypes
(8). One marker protein that differs in its expres-
sion level between the two mouse strains was iden-
tified as glyoxalase I. In addition, we have also
been able to detect a qualitative difference of un-
known nature in another protein. This difference
becomes apparent by a shift in mobility in the first
dimension isoelectric focusing as well as second
dimension SDS gel electrophoresis.
A major goal in the area of mental disorders is
the identification of biomarkers that can catego-
rize subsets of subjects in a more reliable and con-
sistent manner. The approach of selectively breed-
ing mice using an intra-strain approach to focus on
particular traits, in this case anxiety-related behav-
ior, has allowed the identification of protein mark-
ers that are differentially expressed. The predic-
tive validity of these markers to identify different
levels of trait anxiety provides the basis for future
testing including its impact beyond that of a biomar-
ker, i.e. do they contribute to rather than merely
parallel the manifestation of trait anxiety? To an-
swer this question and to further pursue the func-
tional implications of the identified markers we are
planning to extend our screening studies to speci-
mens from patients admitted to the anxiety clinic
at the Max Planck Institute of Psychiatry. As is the
case for all polygenic diseases we do not anticipate
that a single marker will be able to unequivocally
distinguish between clinical phenotypes. Only through
a combination of markers will it be possible to gain
statistical significance to differentiate complex traits
like anxiety-related disorders.
2. Cerebrispinal Fluid Proteome
Short of the analysis of brain biopsies cerebro-
spinal fluid (CSF) is the specimen that is most rele-
vant for human brain disorder biomarker discov-
ery efforts. Since it constantly perfuses brain tis-
sue CSF contains mediators that reflect metabolic
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processes in the brain. Furthermore, CSF can be
obtained in a controlled fashion minimizing the
dangers of variability introduced at the sample col-
lection step. It is hypothesized that the changes in
CSF proteins reflect the pathological alterations in
the function of the central nervous system. There-
fore the comparative analysis of the proteomes of
human CSF from diseased and healthy subjects is
becoming increasingly important for the identifica-
tion of disease-specific proteins. Proteome analysis
of body fluids such as CSF is a great challenge (9).
The major hurdle when it comes to patient sam-
ples is the limiting amount of starting material that
is available to carry out the analysis. Another reason
for the difficult analysis of body fluid proteomes is
their large dynamic range reflected by the pres-
ence of very abundant proteins like albumin and,
in the case of CSF, minute quantities of brain-derived
proteins (9). Further complicating the analysis of
CSF is the possible infiltration of serum proteins that
is caused by a leaky blood-brain barrier that is es-
pecially pronounced in patients with brain disor-
ders. As a consequence it is often impossible to
know if a protein that is found in CSF is derived
from the brain or serum.
Proteome analysis in general involves two stages ;
protein separation followed by identification and
analysis. Multidimensional separations are required
in order to result in an adequate resolution of com-
plex protein mixtures in body fluids. Classical pro-
teomic approaches employ fractionation on the protein
level with the help of two dimensional-polyacrylamide
gel electrophoresis (2D-PAGE). This technique prod-
uces high resolution protein separations resulting
in the display of potentially thousands of protein
spots. Alternatively, tryptic peptides derived from
the proteins in the mixture can be subjected to
shotgun mass spectrometry analysis. In the shot-
gun mass spectrometry approach proteins are di-
gested by specific enzymes into small peptides
and analyzed on-line by mass spectrometry. A
major advantage of the shotgun mass spectrometry
approach is that low abundant proteins can be
identified in the presence of high abundant pro-
teins, a scenario that is often encountered when
analyzing protein mixtures from body fluids like
serum or CSF. We have been able to identify a
large number (over 500) of the constituents of the
human CSF proteome using a combination of
isoelectric focusing and reversed phase chroma-
tography followed by shotgun mass spectrometry
(10,11). After depletion of the most abundant
proteins from the CSF mixture with the help of an
immunoaffinity column the peptides resulting from
a proteolytic digest of the remaining proteins were
first fractionated by isoelectric focusing in an IPG
strip. The extracted peptides were then further
fractionated on a nano reversed phase column and
analyzed on-line by iontrap tandem mass spec-
trometry. Using this strategy we have been able to
greatly increase the number of CSF proteins iden-
tified. Many of these proteins are of low abun-
dance and represent intracellular components such
as signaling proteins and transcription factors.
These findings indicate that intracellular contents
of cells and tissues is released into CSF presum-
ably through apoptotic and necrotic mechanisms.
Although it is difficult to know how many proteins
are exclusively derived from the brain since many
proteins are also expressed in other tissues and
therefore could potentially be introduced into CSF
through its exchange with serum, we now have
evidence that many of the proteins that were
identified in CSF are in fact derived from brain
tissue. This is based on a comparison of the identi-
fied CSF proteins with a recently published hu-
man serum protein database(12). We found pro-
teins with a wide range of isoelectric points using
the described shotgun mass spectrometry ap-
proach. To achieve a comparable coverage of pro-
teins with 2D-PAGE analysis one needs to run
several gels with overlapping pH gradients. This
requires more sample and is often prohibitive
when dealing with human body fluids and tissues.
In order to gauge the sensitivity of our CSF pro-
teome mining efforts we have compared our CSF
protein list against a relational database for mark-
ers for affective and neurological disorders that we
have established using data from the public do-
main. The comparison revealed that our CSF pro-
tein list contains several candidate markers that
have been previously associated with affective and
neurological disorders. This finding confirms that
immunodepletion of abundant proteins followed by
an extensive prefactionation of peptides resulting
after proteolysis of the remaining proteins leads to
a rather sensitive coverage of the CSF protein con-
stituents. This is in part due to the generation of a
smaller dynamic range of the remaining protein
mixture. In addition, due to the smaller amount of
total protein that results from the combination of
immunodepletion and prefractionation a greater
equivalent of the CSF sample can be used during
the shotgun mass spectrometry analysis without
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the risk of overloading the reversed-phase nano
column that is employed on-line with the mass
spectrometer.
3. Biomarker Identification with Cerebrospinal
Fluid Autoantibodies
Next to the classical proteomic efforts geared
towards the analysis of the protein constituents in
CSF (10,11) we have also set out to establish alter-
native strategies for the identification of novel dis-
ease markers for affective disorders. In an effort
that has been funded as an “Exploratory Project”
within the National Genome Research Network (NGFN-2)
we want to exploit the great specificity of the body’s
immune system. Specifically, we are analyzing the
antibody pool that is present in CSF. Autoantibod-
ies against a variety of CNS proteins in serum and
CSF of patients with affective disorders have been
described. An interesting phenomenon supporting
a potential involvement of an autoimmune compo-
nent in affective disorders is the fact that the pat-
tern of disease progression, the age of onset and the
repeating periods of regression and recovery are
very similar between autoimmune diseases and af-
fective disorders. The identification of autoanti-
gens could ultimately lead to novel diagnostic and
therapeutic procedures for an early detection and
treatment of affective disorders. Similar approaches
have already provided valuable information in
other disease areas. These include Type I Autoimmune
Diabetes Mellitus and Rheumatoid Arthritis . Both of
these disorders present examples of T cell-mediated auto-
immune diseases for which autoantibodies have al-
ready found a clinical utility.
It is well known that any endogenous epitope
that shares consensus sequences with exogenous
antigens as well as abnormal protein expression
levels, mutations or impaired chaperone activities
producing misfolded proteins can raise a humoral
or cellular autoimmune response. Hence, the basis
of this approach stands on the hypothesis that all these
factors may trigger an autoimmune response within
the CNS especially in individuals with affective
disorders that are propositioned to immune system
dysfunction and impaired blood-brain barriers. De-
tection of the epitopes of CSF autoantibodies may
reveal candidate mechanisms of affective disorders
and help identify specific biomarkers for them. We
further hypothesize that the presence of markers
for affective diseases is reflected by the appear-
ance of autoantibodies in CSF. These autoantibod-
ies can be used for the identification of their re-
spective autoantigen counterparts that consequently
represent markers of disease.
In preliminary experiments we have used CSF
antibodies in a Western blot with brain proteins as
targets. For this purpose we subjected a human
brain protein extract to SDS gel electrophoresis
and subsequently transferred the proteins to a mem-
brane. Each slot was then probed separately with
CSF. Although the results demonstrate that spe-
cific autoantibodies are present in CSF and can be
detected using biochemical techniques the iden-
tity of the autoantigens remains obscure. The re-
alization that the identification of brain autoanti-
gens is limited by the CSF sample that is available
prompted us to explore alternative experimental
strategies. The sensitivity of the phage display ap-
proach that we employ in our studies will greatly
assist in the discovery of autoantigens that are ex-
pressed at low levels.
OUTLOOK
The proteomics oriented strategies that I have
outlined above are only part of a multidisciplinary
effort that a number of research groups are pursu-
ing at the Max Planck Institute of Psychiatry in order
to improve our understanding of affective and neu-
rological disorders. Other approaches include tar-
geted as well as global genotyping efforts and
microarray studies for differential RNA expression.
An integrated evaluation of the data that are ob-
tained by all the holistic approaches in combina-
tion with clinical and epidemiological data will
eventually not only increase our understanding of
disease mechanisms but subsequently also enable
us to develop more specific and individualizedc
medi-cines and therapies.
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